David Harlan to Immunoconjugates
This is a "connection" page, showing publications David Harlan has written about Immunoconjugates.
Connection Strength
0.344
-
Knechtle SJ, Kirk AD, Fechner JH, Hong X, Dong Y, Hamawy MM, Harlan DM. Inducing unresponsiveness by the use of anti-CD3 immunotoxin, CTLA4-Ig, and anti-CD40 ligand. Transplant Proc. 1999 May; 31(3B Suppl):27S-28S.
Score: 0.158
-
Tadaki DK, Craighead N, Saini A, Celniker A, Burkly LC, Lee KP, Chute JP, Harlan DM, Kirk AD. Costimulatory molecules are active in the human xenoreactive T-cell response but not in natural killer-mediated cytotoxicity. Transplantation. 2000 Jul 15; 70(1):162-7.
Score: 0.043
-
Saha B, Chattopadhyay S, Germond R, Harlan DM, Perrin PJ. CTLA4 (CD152) modulates the Th subset response and alters the course of experimental Leishmania major infection. Eur J Immunol. 1998 12; 28(12):4213-20.
Score: 0.038
-
Horspool JH, Perrin PJ, Woodcock JB, Cox JH, King CL, June CH, Harlan DM, St Louis DC, Lee KP. Nucleic acid vaccine-induced immune responses require CD28 costimulation and are regulated by CTLA4. J Immunol. 1998 Mar 15; 160(6):2706-14.
Score: 0.037
-
Kirk AD, Harlan DM, Armstrong NN, Davis TA, Dong Y, Gray GS, Hong X, Thomas D, Fechner JH, Knechtle SJ. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci U S A. 1997 Aug 05; 94(16):8789-94.
Score: 0.035
-
Saha B, Jaklic B, Harlan DM, Gray GS, June CH, Abe R. Toxic shock syndrome toxin-1-induced death is prevented by CTLA4Ig. J Immunol. 1996 Nov 01; 157(9):3869-75.
Score: 0.033